LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, at 10:00 a.m.

Lexicon will also be participating in 1x1 investor meetings at the 2026 Jefferies Biotech on the Beach Summit, March 10–11, and at the Barclays 28th Global Healthcare Conference, March 10-12.

A live recording and replay of the Leerink fireside chat can be accessed via the Events page of the Company’s website at .

About Lexicon Pharmaceuticals     

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit .

For Investor and Media Inquiries: 

Lisa DeFrancesco  

Lexicon Pharmaceuticals, Inc. 

 



EN
03/03/2026

Underlying

LXRXLexicon Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lexicon Pharmaceuticals Inc.

 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Announces Three Presentations at the American College of Cardi...

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced three presentations of sotagliflozin clinical data during the American College of Cardiology (ACC) Annual Meeting. The congress is being held March 28-30 in New Orleans, Louisiana. Lexicon will present d...

March 24, 2026 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase ...

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million near-term milestone payments and is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, March 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXR...

March 23, 2026 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon to Present Data on Effect of Kidney Function on the Long-term ...

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes Post hoc data analysis concluded that sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improved glycemic control after one year in patients with normal and mildly reduced kidney function THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function...

March 11, 2026 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results ...

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- (Na...

March 5, 2026 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investo...

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, at 10:00 a.m. Lexicon will also be participating in 1x1 investor meetings at the 2026 Jefferies Biotech on the Beach Summit, March 10–11, and at the Barclays 28th Global Healthcare Conference, March 10-12. A live recording and re...

March 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch